| 2.28 -0.18 (-7.32%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.47 | 1-year : | 4.18 |
| Resists | First : | 2.97 | Second : | 3.57 |
| Pivot price | 2.29  |
|||
| Supports | First : | 1.99 | Second : | 1.65 |
| MAs | MA(5) : | 2.42 |
MA(20) : | 2.27 |
| MA(100) : | 2.2 |
MA(250) : | 2.73 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.6 |
D(3) : | 55.2 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 6.51 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CCCC ] has closed above bottom band by 47.6%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.47 | 2.47 - 2.48 |
| Low: | 2.18 - 2.19 | 2.19 - 2.21 |
| Close: | 2.26 - 2.28 | 2.28 - 2.3 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Thu, 16 Oct 2025
Revenues Working Against C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Share Price Following 38% Dive - 富途牛牛
Thu, 16 Oct 2025
C4 Therapeutics (CCCC) to Raise $125M Through Stock and Warrant Offering - GuruFocus
Thu, 16 Oct 2025
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - Investing News Network
Thu, 16 Oct 2025
$125M Upfront — C4 Therapeutics Prices Offering to Fund Cemsidomide Trials; May Reach $349.7M - Stock Titan
Thu, 16 Oct 2025
C4 Therapeutics, Inc. Presents Phase 1 Trial Data for Cemsidomide - TradingView
Wed, 01 Oct 2025
C4 Therapeutics Announces Clinical Trial Collaboration and - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 3,520 (K) |
| Shares Short P.Month | 3,780 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | 0 % |
| Operating Margin | -441 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | -53 % |
| Qtrly Rev. Growth | -46.3 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | -1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -1.44 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 4.73 |
| Price to Cash Flow | -1.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|